secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexalin Technology, Inc. (NXL)
CIK:        0001527352
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001829126-23-003881
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nexalin forms JV with Wider Come to commercialize tACS devices in Asia; Wider funds ops and 4 trials
--------------------------------------------------------------------------------

- JV ownership: Wider 52%, Nexalin 48%; will market Gen-2 tACS devices in China and Asia Pacific.
- Wider to fund all JV operating expenses for 12 months, then pro rata funding.
- Wider obligated to fund and conduct four clinical trials (insomnia, depression, other) using Gen-2 devices.
- Previously Wider was an authorized distributor; role now expanded to include clinical development.
- NMPA approval for insomnia and depression already in place for tACS device.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527352/000182912623003881/0001829126-23-003881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527352/000182912623003881/nexalin_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-23-003881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer